Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...

Pfizer names oncology head Chris Boshoff as R&D chief. By Sriparna Roy and Michael Erman. November 20, 2024 4:05 PM UTC Updated November 20, 2024 The Pfizer logo is pictured on ...

Pfizer Oncology. Pfizer saw a 31% ... The market simply doesn't think PFE can keep paying the dividend. I think the better strategy is to halve the dividend and use the saving to pay down debt.

Pfizer Inc. (PFE) named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been ...

Pfizer will pay Montai up to $700 million in up-front and milestone payments, according to Montai CEO Margo Georgiadis. The two firms have worked together for several months and expect “some ...

Pfizer is laying down new pieces for its leadership team structure, selecting Jeffrey Legos, Ph.D., to replace interim Chief Oncology Officer Roger Dansey, M.D. As head of oncology, Legos will ...